Study of AZD9829 in CD123+ Hematological Malignancies

Inclusion Criteria

• ≥18 years of age;
• CD123+ hematologic malignancy based on flow cytometry or immunohistochemistry by local laboratory;
• R/R AML (except APL);
• R/R HR-MDS with ≥5% bone marrow blast at time of inclusion;
• Had at least 1 prior line of therapy at currents histology, and have no available treatment options;
• ECOG performance status of ≤ 2. The above is a summary, other inclusion criteria details may apply.

Exclusion Criteria

• Active CNS leukemia;
• Previous treatment with any CD123 targeting therapy;
• Prior allogeneic HSCT, within 90 or cell therapy within 60 of start of therapy;
• Active GVHD that requires immunosuppressive treatment within 4 weeks prior to start of AZD9829;
• History of other malignancy(with certain exceptions);
• Active and uncontrolled infections;
• Unresolved AEs ≥2 Grade, from prior therapies. The above is a summary, other exclusion criteria details may apply .